Denali Therapeutics Inc
DNLIHealthcare|Biotechnology|USA
$25.68
-1.53 (-5.62%)
Tangible Book
$5.61
Clinical Trials (25)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05371613 A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) | Mucopolysaccharidosis II | P2P3 | Recruiting | 63 | RCT, Double-blind | tividenofusp alfa, idursulfase |
| NCT06602193 Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | Parkinson Disease | P2 | Active | 50 | RCT, Double-blind | BIIB122 225 mg |
| NCT06181136 Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A) | Mucopolysaccharidosis Type IIIA | P1P2 | Active | 20 | Open-label | DNL126 |
| NCT05262023 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) | Frontotemporal Dementia | P1P2 | Active | 85 | RCT, Double-blind | DNL593, Placebo |
| NCT04251026 A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome | Mucopolysaccharidosis II | P1P2 | Active | 47 | Open-label | tividenofusp alfa |
| NCT07328451 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease | Alzheimer Disease, Early Onset | P1 | Recruiting | 68 | RCT, Double-blind | DNL628, Placebo |
| NCT07354724 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease | Late-onset Pompe Disease | P1 | Recruiting | 32 | Open-label | DNL952 |
| NCT05418673 A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale | Parkinson Disease | P3 | Terminated | 7 | RCT, Double-blind | BIIB122, BIIB122-Matching Placebo |
| NCT06075537 An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 | Mucopolysaccharidosis II | P2P3 | By Invite | 99 | Open-label | tividenofusp alfa |
| NCT05842941 HEALEY ALS Platform Trial - Regimen G DNL343 | Amyotrophic Lateral Sclerosis | P2P3 | Completed | 249 | RCT, Double-blind | DNL343, Matching Placebo |
| NCT05348785 A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 | Parkinson Disease | P2 | Completed | 650 | RCT, Double-blind | BIIB122, BIIB122-Matching Placebo |
| NCT04551534 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 122 | RCT, Double-blind | DNL201, Placebo |
| NCT03757325 Study to Evaluate DNL747 in Subjects With Alzheimer's Disease | Alzheimer Disease | P1 | Completed | 16 | RCT, Double-blind | DNL747, Placebo |
| NCT05006352 A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | P1 | Completed | 29 | RCT, Double-blind | DNL343, Placebo |
| NCT05119790 A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects | Healthy Volunteers | P1 | Completed | 7 | Open-label | [14C] BIIB122 ([14C] DNL151) |
| NCT06281158 A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants | Healthy Volunteers | P1 | Completed | 7 | Open-label | [14C]-DNL343 |
| NCT04581772 A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 31 | RCT, Open-label | DNL343, Placebo, DNL343 |
| NCT05005338 A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects | Healthy Volunteers | P1 | Completed | 8 | Open-label | BIIB122 (DNL151), [14C] BIIB122 ([14C] DNL151) |
| NCT04268784 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 96 | RCT, Double-blind | DNL343, Placebo |
| NCT03710707 Study to Evaluate DNL201 in Subjects With Parkinson's Disease | Parkinson Disease | P1 | Completed | 29 | RCT, Double-blind | DNL201, Placebo |
| NCT05450549 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants | Healthy Participant | P1 | Completed | 47 | RCT, Double-blind | DNL919, Placebo |
| NCT03757351 Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | P1 | Terminated | 15 | RCT, Double-blind | DNL747, Placebo |
| NCT04557800 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 186 | RCT, Double-blind | DNL151, Placebo |
| NCT04007536 A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome | Mucopolysaccharidosis II | Completed | 18 | — | — | |
| NCT05523206 A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome) | Mucopolysaccharidosis III-A | Completed | 15 | — | — |